ClinicalTrials.gg
RecruitingNCT07855887Updated Oct 2, 2026

Calcium Gluconate Activated in Anterior Disc Displacement With Reduction of the Temporomandibular Joint

An interventional study of activated platelet-rich plasma and non-activated platelet-rich plasma in Temporomandibular Joint Disorders, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Cairo University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Temporomandibular Joint Disorders by Cairo University — 8 open to participants now, 9 under way, none of them phase 3. Temporomandibular Joint Disorders · Cairo University.

Planned enrollment
18th of 21
20 · median 29
Started
2026
with 2 others
No phase
20 of 30
7 open now
Registered
30th of 30
by date

Among the 30 studies in Temporomandibular Joint Disorders by Cairo University, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 20 with no phase, and was the 30th registered.

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

Browse Temporomandibular Joint Disorders studies →

Open to participants now

8 of the 30 studies in Temporomandibular Joint Disorders by Cairo University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Temporomandibular Joint Disorders by Cairo University, or all of them as a file.
02

Study summary

To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement with Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range

Read the detailed description

To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement With Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range.

Although laboratory evidence indicates that activation with Calcium Gluconate significantly enhances growth factor release compared to non-activated (resting) PRP, it remains clinically unproven whether this biochemical advantage translates into superior symptomatic relief and functional disc repositioning in TMJ patients. This trial seeks to determine if the additional step of activation yields a statistically significant clinical benefit over the simpler, non-activated technique.

By combining the biologically optimized injectate (Calcium Gluconate-Activated PRP) with the anatomically specific retrodiscal injection site-which is critical for addressing disc instability-this study aims to define a superior, evidence-based protocol. Determining the efficacy of this specific combination is essential for establishing a "gold standard" for non-surgical ADDWR management.

03

Conditions studied

  • Temporomandibular Joint Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Clinical and MRI diagnosis of ADDWR per DCTMD criteria.
  • Baseline VAS pain score 4-10.
  • Failure of at least 2 conservative treatments (splint therapy, physiotherapy, NSAIDs) for 3 months.
  • Written .

Exclusion criteria

Exclusion Criteria:

    • Systemic inflammatory arthritis (Rheumatoid arthritis, etc.).

      • Recent TMJ surgery or intra-articular injection within the last 6 months.
      • Pregnancy or lactation.
      • Active TMJ infection or .
      • Coagulopathy or anticoagulant therapy.
      • to MRI (e.g., pacemaker).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    activated platelet-rich plasma

    Intra-articular retro discal injection of autologous platelet-rich plasma (PRP)

    Procedure: activated platelet-rich plasma

  • Active comparator
    non-activated platelet-rich plasma

    Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma

    Procedure: non-activated platelet-rich plasma

Interventions

  • Procedureactivated platelet-rich plasma

    Intra-articular retrodiscal injection of autologous platelet-rich plasma (PRP) activated with 0.5 milliliters of 10% sterile calcium gluconate per 5 milliliters of prepared PRP, administered as a single anatomical landmark-guided injection into the retrodiscal tissue.

  • Procedurenon-activated platelet-rich plasma

    Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma, prepared using identical double-centrifugation technique and administered using identical injection protocol and volume

06

What researchers measure

Primary outcomes

  1. Maximal Interincisal Opening (MIO)

    measuring in millimeters using ruler

    Time frame: 3 months

Secondary outcomes

  1. Pain Intensity

    Visual Analog Scale (0-10)

    Time frame: 3 months

  2. Return of disc to normal position

    using MRI imaging

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.

Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 3 months is below that.

Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jul 25, 2026
Primary completionEst.
Oct 25, 2026
CompletionEst.
Nov 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07855887
Lead sponsor
Cairo University
Responsible party
Mohamed Ahmed Osama Madkour ElSayed (Master's degree Student, Cairo University) — Principal investigator
First posted
Oct 2, 2026
Start date
Jul 25, 2026
Primary completion
Oct 25, 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Mohamed A. Osama, BDS
Contact
mohamed.madkour@dentistry.cu.edu.eg
01013127607

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion